CryoPort, Inc. (CYRX)

In our clinic and research operations, managing the cold chain for cell and gene therapies is non-negotiable. Seeing that CryoPort is currently supporting 779 global clinical trials and 22 commercially approved CGTs gives us confidence in their logistical infrastructure. However, looking at the financial reports for Q2 2026, while Life Sciences Services revenue grew 15% year-over-year to $49.0 million, the net loss widened to $8.26 million compared to net income a year ago. We are monitoring how these supply chain costs translate into trial continuity, especially given their heavy regional concentration in the Americas at 74.5%.

On our desk, CYRX is presenting a classic valuation puzzle following the Q2 2026 print. Total revenue grew 8% year-over-year to $49.0 million, and BioStorage/BioServices saw an impressive 25% expansion. Yet, the alternative data ecosystem points to a different story, with AltIndex assigning a 52/100 'Hold' score due to lagging job postings despite a minor tick-up in web traffic. With the stock hovering around $15.09 to $15.93 and a market cap near $772M to $794M, institutional sentiment is mixed. We are treating this as a range-bound asset until clearer margin expansion materializes beyond the positive EBITDA milestone.

From a quantitative perspective, the technicals and fundamental metrics for CYRX require a disciplined approach. The trailing P/E sits around 11.4 with a trailing EPS of $1.40 and an ROE of 15.3%, but the massive swing from net income last year to an $8.26 million net loss in Q2 2026 introduces volatility. Analysts tracking the name have a consensus price target of $19, offering potential upside from current levels around $15.93. When evaluating execution protocols for their commercial cell and gene therapy revenue—which grew 9% to $9.4 million—risk models demand close tracking of their heavy geographic exposure before adding aggressive long exposure.